Parkinson's Disease Trial, Recruiting NCT05765110 Sponsor: Insel Gruppe AG, University Hospital Bern Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT05765110
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

For People with Parkinson's Disease

Who might be able to join this trial:

  • People who are willing and able to sign a written consent form
  • People diagnosed with Parkinson's disease (the type with no known specific cause) according to Movement Disorders Society guidelines
  • People aged between 31 and 75 years old
  • People who are being treated with or without a specific type of brain stimulation device (deep brain stimulation in a region called the subthalamic nucleus), or who have no such device
  • People who speak German or French fluently

Who may not be able to join:

  • People whose speech difficulties are caused by a condition other than Parkinson's disease, such as a stroke or a muscle weakness condition
  • People who have been clinically diagnosed with aphasia (a condition affecting the ability to speak or understand language)
  • People who have a brain condition other than Parkinson's disease, such as Alzheimer's disease, multiple sclerosis, stroke, epilepsy, or similar conditions
  • People who show signs of significant cognitive (thinking and memory) difficulties, based on a standard assessment scoring below 24 out of 30
  • People who are currently experiencing depression with active thoughts of suicide

For Healthy Volunteers (Control Group)

Who might be able to join this trial:

  • People who are willing and able to sign a written consent form
  • Adults aged between 50 and 70 years old
  • People who speak German or French fluently

Who may not be able to join:

  • People who have been diagnosed with Parkinson's disease
  • People who show signs of significant cognitive (thinking and memory) difficulties, based on a standard assessment scoring below 24 out of 30
  • People who have a brain condition such as Alzheimer's disease, multiple sclerosis, stroke, epilepsy, or similar conditions
  • People who have been clinically diagnosed with aphasia, speech difficulties (dysarthria), or stuttering
  • People who have been diagnosed with a psychiatric illness as defined by standard diagnostic guidelines (DSM-V) (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Paul Krack, Prof., Insel Gruppe AG, University Hospital Bern

Phone: 31 66 4 03 71

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Insel Gruppe AG, University Hospital Bern
Registry
ClinicalTrials.gov
Start date
3 January 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇿 Czechia 🇨🇭 Switzerland

Primary endpoints

Part I: Changes from baseline in best acoustic speech variables to detect changes of dopaminergic and stimulation motor effect in Parkinson's disease patients; Part II: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation neuropsychological effect in Parkinson's disease patients; Part III: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation cognitive effect in Parkinson's disease patients; Part III: Changes from baseline in best acoustic and linguistic speech...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov